Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 2Efficacy & side effects
1(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Other(3)

Detailed Status

unknown3
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 21 (100.0%)

Trials by Status

not_yet_recruiting125%
unknown375%

Recent Activity

0 active trials
Showing 4 of 4
not_yet_recruitingphase_2

Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

NCT07082764
unknown

Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery

NCT05564884
unknown

PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility

NCT03026309
unknown

Heavy Light Chain in Chronic Lymphocytic Leukemia

NCT02377869

Clinical Trials (4)

Showing 4 of 4 trials
NCT07082764Phase 2

Safety and Efficacy Study of TAR-0520 Gel in Prevention of Taxane-induced Peripheral Neuropathy

Not Yet Recruiting
NCT05564884

Neonatal SARS-CoV-2 Anti-spike Protein Receptor-binding Domain Antibodies at Delivery

Unknown
NCT03026309

PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility

Unknown
NCT02377869

Heavy Light Chain in Chronic Lymphocytic Leukemia

Unknown

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4